Antiproliferative compounds and methods of use thereof
US-2024207255-A1 · Jun 27, 2024 · US
Methods and compositions for enhancement of ability to concentrate
US10369185B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10369185-B2 |
| Application number | US-201515312882-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 22, 2015 |
| Priority date | May 23, 2014 |
| Publication date | Aug 6, 2019 |
| Grant date | Aug 6, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A composition for enhancement of ability to concentrate and method of improving ability to concentrate using alanylglutamine or a salt of alanylglutamine as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of improving ability to concentrate in a subject performing an endurance activity, comprising the step of administering a fluid comprising an effective amount of alanylglutamine or a salt thereof to the subject, wherein the amount of fluid comprising the effective amount of alanylglutamine or a salt thereof consumed by the subject is less than the amount of fluid lost by the subject during the activity. 2. The method of claim 1 , wherein the alanylglutamine or salt thereof is administered in an amount of 5 mg or more and 10,000 mg or less per day. 3. The method of claim 1 , wherein the alanylglutamine or salt thereof is administered in an amount of 50 mg or more and 5,000 mg or less per day. 4. The method of claim 1 , wherein the alanylglutamine or salt thereof is administered in an amount of 500 mg or more and 3,000 mg or less per day. 5. The method of claim 1 , wherein the fluid comprises alanylglutamine or salt thereof in a concentration of 600 mg/L or more and 2 g/L or less. 6. The method of claim 1 , wherein the endurance activity is an endurance exercise lasting at least 60 minutes.
Assignees
Inventors
Classifications
Drugs for disorders of the nervous system · CPC title
Adding ingredients (adding preservatives A23B70/10) · CPC title
Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title
- A61K38/05Primary
Dipeptides · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10369185B2 cover?
- A composition for enhancement of ability to concentrate and method of improving ability to concentrate using alanylglutamine or a salt of alanylglutamine as an active ingredient.
- Who is the assignee on this patent?
- Kyowa Hakko Bio Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K38/05. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).